United States News Beep
  • News Beep
  • Breaking News
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
United States News Beep
United States News Beep
  • News Beep
  • Breaking News
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
Kobach announces $720 million settlement with opioid manufacturers
MMedication

Kobach announces $720 million settlement with opioid manufacturers

  • July 18, 2025

TOPEKA, Kan. (WIBW) – Kansas Attorney General Kris Kobach on Tuesday announced an approximate $720 million nationwide settlement with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis.

Kansas stands to receive approximately $5.7 million in settlement funds, according to a news release from Kobach’s office.

“We are holding these companies accountable for the human suffering caused by years of their illegal marketing practices,” Kobach said in the news release. “These dollars will help save lives, because the funds will be used to prevent and treat drug addiction throughout Kansas.”

Kansas Attorney General Kris Kobach on Tuesday announced an approximate $720 million...Kansas Attorney General Kris Kobach on Tuesday announced an approximate $720 million nationwide settlement with eight manufacturers of opioid pills.(John Hanna | AP)

The eight defendants and the total amount they will pay in funds to address the opioid crisis as part of the deal are:

Mylan — now part of Viatris: $284,447,916 paid over nine years Hikma: $95,818,293 paid over one to four years Amneal: $71,751,010 paid over 10 years Apotex: $63,682,369 paid in a single year Indivior: $38,022,450 paid over four years Sun: $30,992,087 paid over one to four years Alvogen: $18,680,162 paid in a single year Zydus: $14,859,220 paid in a single year 

In addition to these abatement payments, several of the settlements allow states to receive free pharmaceutical products or cash in lieu of this product, the news release said.

Additionally, seven of the companies — not including Indivior — are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders.

Indivior has agreed not to manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.

North Carolina, California, Colorado, Illinois, New York, Oregon, Tennessee, Utah, and Virginia attorneys general offices negotiated the settlements on behalf of Kansas and several other states, the news release said.

Copyright 2025 WIBW. All rights reserved.

  • Tags:
  • Health
  • Medication
United States News Beep
www.newsbeep.com